Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?

被引:2
作者
Dave, Prashil [1 ]
Vela, Elisa Pallares [1 ]
Cancarevic, Ivan [2 ]
机构
[1] Calif Inst Behav Neurosci & Psychol, Gen Med, Fairfield, CA 94534 USA
[2] Calif Inst Behav Neurosci & Psychol, Internal Med, Fairfield, CA USA
关键词
cytokine release syndrome (crs); chimeric antigen receptor t-cell therapy; cancer-immunotherapy; management strategies; leukaemia; oncology clinical trials; relapsing multiple myeloma; incidence rate; MANAGEMENT;
D O I
10.7759/cureus.17709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chimeric antigen receptor T-cell (CAR-T) therapy is a new advancement in hematology and oncology with its use in treating many refractory malignancies. Cytoidne release syndrome (CRS) is CAR-T's clinically hazardous side effect, ranging from mild to life-threatening events. It was one of the first side effects detected with CAR-T. We conducted a literature review using PubMed (MeSH) to study CRS incidence after the administration of CAR-T to reflect its clinical importance. Nine studies are mentioned, with a total of 1357 patients enrolled for different types of refractory/relapsed cancers, and an average incidence of CRS of 64% is being noted. We have also stated numerous studies which mentioned the use and effectiveness of the commonly used drugs like tocilizumab, corticosteroids, and some new drugs. Although statistical data on CRS's conservative and supportive management is not available, the role of different supportive measures is evident. An overview of how it sets the framework of a peri-management approach has been considered. Through heightened incidence and relatively complex management of CRS, we would like to raise the question of the need for early prophylaxis against CRS when considering CAR-T. The need for more clinical trials in the future to prove the effectiveness of the latter is stated.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Chimeric antigen receptor T-cell toxicity
    Baymon, DaMarcus E.
    Boyer, Edward W.
    CURRENT OPINION IN PEDIATRICS, 2019, 31 (02) : 251 - 255
  • [42] Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
    Perrinjaquet, Claire
    Desbaillets, Nicolas
    Hottinger, Andreas F.
    CURRENT OPINION IN NEUROLOGY, 2019, 32 (03) : 500 - 510
  • [43] Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma
    Hoda, Daanish
    Richards, Robert
    Faber, Edward A.
    Deol, Abhinav
    Hunter, Bradley D.
    Weber, Elizabeth
    DiFilippo, Heather
    Henderson-Clark, Toni
    Meaux, Linda
    Crivera, Concetta
    Riccobono, Carrie
    Garrett, Ashraf
    Jackson, Carolyn C.
    Fowler, Jessica
    Theocharous, Panteli
    Stewart, Raj
    Lorden, Andrea L.
    Porter, David L.
    Berger, Ariel
    FUTURE ONCOLOGY, 2022, 18 (19) : 2415 - 2431
  • [44] Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
    Wang, Xue
    Zhao, Lina
    Wang, Jing
    Yao, Yue
    Wang, Jiaojiao
    Ji, Shengwei
    Hua, Tian
    Wang, Shiyuan
    Cheng, Hai
    Shi, Ming
    Li, Zhenyu
    Zeng, Lingyu
    Zheng, Junnian
    Xu, Kailin
    Cao, Jiang
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy
    Zu, Cheng
    Wu, Shenghao
    Zhang, Mingming
    Wei, Guoqing
    Xu, Huijun
    Cui, Jiazhen
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    CYTOTHERAPY, 2023, 25 (11) : 1167 - 1175
  • [46] Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
    Marar, Rosalyn I. I.
    Abbasi, Muhannad Aboud
    Prathivadhi-Bhayankaram, Sruti
    Daryanani, Andres
    Villarraga, Hector
    Anavekar, Nandan
    Bhatt, Vijaya Raj
    Paludo, Jonas
    JCO ONCOLOGY PRACTICE, 2023, 19 (06) : 331 - +
  • [47] Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice
    Dushenkov, Anna
    Jungsuwadee, Paiboon
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (05) : 1217 - 1225
  • [48] Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
    Zhou, Wenyujing
    Chen, Weihong
    Wan, Xiaochun
    Luo, Changru
    Du, Xin
    Li, Xiaoqing
    Chen, Qian
    Gao, Ruiwen
    Zhang, Xiaohan
    Xie, Mei
    Wang, Mingjun
    FRONTIERS IN GENETICS, 2022, 12
  • [49] Trypanosoma cruzi Reactivation After Chimeric Antigen Receptor T-Cell Therapy
    Alahmdi, Bayan
    Kaur, Avneet
    Jacobs, Samantha E.
    Sullivan, Timothy
    Barghash, Maya
    Taimur, Sarah
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (01):
  • [50] Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
    Rubin, Daniel B.
    Al Jarrah, Ali
    Li, Karen
    LaRose, Sarah
    Monk, Andrew D.
    Ali, Ali Basil
    Spendley, Lauren N.
    Nikiforow, Sarah
    Jacobson, Caron
    Vaitkevicius, Henrikas
    JAMA NEUROLOGY, 2020, 77 (12) : 1536 - 1542